Citations

Clear

4610 citation(s) found for "Lu, Brian".

CTNI-17. APPLICATION OF THE GBM-X DATA PLATFORM TO ESTIMATE TREATMENT EFFECTS OF THE EXPERIMENTAL THERAPIES OF THE RANDOMIZED PHASE 2 INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPIES
Rahman, Rifaquat , Trippa, Lorenzo , Fell, Geoffrey, Lee, Eudocia Q. , Arrillaga‐Romany, Isabel , Welch, Mary , Colman, Howard , Hepel, Jaroslaw T., Elinzano, Heinrich, Schiff, David , Chukwueke, Ugonma , Nayak, Lakshmi , Batchelor, Tracy T. , Rinne, Mikael L. , Lu‐Emerson, Christine , Haas‐Kogan, Daphne A. , Cagney, Daniel , Aizer, Ayal A. , Doherty, Lisa, Reardon, David A. , Wen, Patrick Y. , Fell, Geoffrey G. , Arrillaga‐Romany, Isabel , Touat, Mehdi , Drappatz, Jan , Galanis, Evanthia , Ahluwalia, Manmeet S. , Colman, Howard , Nabors, Burt , Beroukhim, Rameen , McFaline-Figueroa, J Ricardo , Kaley, Thomas , Mellinghoff, Ingo K. , Bi, Wenya Linda , Arnaout, Omar M. , Peruzzi, Pier Paolo , Tanguturi, Shyam K , Santagata, Sandro , Meredith, David M. , Chiocca, E Antonio , Alexander, Brian M. , Ligon, Keith L , Wen, Patrick Yung

Mayo Clinic

Neuro-Oncology | November 11, 2023 | Volume: 25 | Issue: Supplement_5 | Pages: v76-v77

10.1093/neuonc/noad179.0299 Get It

Abstract BACKGROUND Leveraging external data has the potential to increase efficiency and precision of drug development in glioblastoma by complementing or replacing data from in-trial controls. We used an external control arm (ECA) to re-analyze data of the abemaciclib, neratinib and CC-115 arms of the Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) trial. METHODS INSIGhT (NCT02977780) is an ongoing phase 2 adaptive platform trial in newly diagnosed MGMT unmethylated glioblastoma with a shared control arm of patients receiving radiation therapy with concurrent and maintenance temozolomide. The initial experimental arms (abemaciclib, neratinib, CC-115) have not shown a survival benefit relative to the shared control arm. We re-analyzed the experimental arm data and replaced the shared control arm with an ECA. The ECA was developed from a collection of trial datasets and real-world data available through the Glioblastoma External (GBM-X) Data Platform (). Propensity score matching was used to adjust for possible differences between pretreatment covariates (age, sex, resection, KPS) in the ECA and shared control arm. Cox proportional hazards models were used to estimate treatment effects. RESULTS On INSIGhT, patients were randomized to abemaciclib (n = 74), neratinib (n = 80), and CC-115 (n = 12). There were 687 unmethylated MGMT patients in the GBM-X ECA. After propensity score matching, there was no significant treatment effect associated with abemaciclib (HR 1.091, 95%CI:0.834-1.433, p = 0.536), neratinib (HR = 1.043, 95%CI:0.787-1.383, p = 0.770), or CC-115 (HR 1.088, 95%CI:0.834-1.433, p = 0.794) compared to the ECA. CONCLUSION In comparison to an ECA, there was no significant survival benefit with abemaciclib, neratinib and CC-115. Treatment effects estimates were similar to the primary analyses based on the original shared control arm of INSIGhT. The use of external control arms in early phase testing of new therapies is supported by our findings and could significantly reduce costs and time to conduct trials in newly diagnosed glioblastoma.
CTNI-73. ALLIANCE A071601: PHASE II TRIAL OF BRAF/MEK INHIBITION IN NEWLY DIAGNOSED PAPILLARY CRANIOPHARYNGIOMAS
Twohy, Erin , Geyer, Susan, Gerstner, Elizabeth R. , Kabat, Brian, Thierauf, Julia , Ruff, Michael W. , Reardon, David A. , Cohen, Adam L. , Fuente, Macarena de la, Lesser, Glenn J. , Campian, Jian , Agarwalla, Pankaj K., Kumthekar, Priya , Mann, Bhupinder, Vora, Shivangi, Knopp, Michael, Iafrate, A. John , Brown, Paul D. , Barker, Frederick G., Brastianos, Priscilla K. , Kaufmann, Timothy J. , Tabrizi, Shervin , Bota, Daniela A. , Knopp, Michael V. , Curry, William T. , Cahill, Daniel P. , Shih, Helen A. , Santagata, Sandro , Galanis, Evanthia

Mayo Clinic

Neuro-Oncology | November 11, 2023 | Volume: 25 | Issue: Supplement_5 | Pages: v94-v94

10.1093/neuonc/noad179.0355 Get It

Abstract BACKGROUND Craniopharyngiomas, primary brain tumors of the pituitary-hypothalamic axis, can cause significant clinical sequelae. Treatment using surgery, radiation, or both often entails significant morbidity. In prior work, we demonstrated that ninety-five percent of papillary craniopharyngiomas (PCP) harbor BRAF V600E mutations (Brastianos et al. Nature Genetics 2014). In this multicenter National Cancer Institute cooperative group trial (Alliance A071601), we evaluated the safety and efficacy of BRAF/MEK inhibition in patients with PCP without prior irradiation. METHODS Eligible patients, with measurable disease and whose PCP screened positively for BRAF mutations, without prior radiation, received the BRAF/MEK inhibitor combination vemurafenib/cobimetinib in 28-day cycles. The primary endpoint of objective response rate at 4 months based on centrally determined volumetric data was evaluated in 16 patients on this single arm phase 2 trial. RESULTS Based on volumetric response criteria by central radiology review, 15 of 16 patients (94%; 95% CI: 70% to 100%) had a durable objective partial response to therapy. Thus, this study met primary endpoint for overall response rate. The median tumor reduction was 91% (range of 68% to 99%). Median follow-up was 22 months (95% CI: 19 to 30 months) and median number of treatment cycles was 8. Median progression-free survival and duration of response were not yet reached. Three patients progressed during follow-up after therapy was discontinued; none have died. The sole non-responder stopped treatment after eight days due to toxicity. Grade 3 toxicities at least possibly related to treatment occurred in 12 patients (rash in 6 patients). Grade 4 toxicities were observed in two patients: hyperglycemia (n=1) and increased creatine phosphokinase (n=1). Three patients discontinued treatment for adverse events. CONCLUSIONS Our study indicates that BRAF/MEK inhibitors are a safe and effective treatment for PCP without prior irradiation. Support: U10CA180821, U10CA180882; U24CA196171, U10CA180868 (NRG); Genentech; . ClinicalTrials.gov Identifier: NCT03224767.
Predictors of Respiratory Failure Development in a Multicenter Cohort of Inpatients With Cirrhosis
Bajaj, Jasmohan S. , Kamath, Patrick S. , Reddy, K. Rajender , Keaveny, Andrew P. , Duarte‐Rojo, Andrés , Kappus, Matthew R. , Verna, Elizabeth C. , Biggins, Scott W. , Vargas, Hugo E. , Shaw, Jawaid , Dahiya, Monica , Filipek, Natalia, Wegermann, Kara , Cabello, Ricardo , Bera, Chinmay , Thuluvath, Paul J. , Keaveny, Andrew P , Duarte-Rojo, Andres , Kappus, Matthew R , Albhaisi, Somaya , Fallahzadeh, Mohammad Amin , Wegermann, Kara , Bera, Chinmay , BUSH, BRIAN J. , Thacker, Leroy R , Wong, Florence , Vargas, Hugo E , Asrani, Sumeet K. , Tandon, Puneeta , Albhaisi, Somaya , Thacker, Leroy R. , Wong, Florence

Mayo Clinic

American Journal of Gastroenterology | November 8, 2023 | Volume: 119 | Issue: 4 | Pages: 712-718

10.14309/ajg.0000000000002574 | PMID 37938163 Get It

INTRODUCTION: Hospitalized patients with cirrhosis can develop respiratory failure (RF), which is associated with a poor prognosis, but predisposing factors are unclear. METHODS: We prospectively enrolled a multicenter North American cirrhosis inpatient cohort and collected admission and in-hospital data (grading per European Association for the Study of Liver-Chronic Liver Failure scoring system, acute kidney injury [AKI], infections [admission/nosocomial], and albumin use) in an era when terlipressin was not available in North America. Multivariable regression to predict RF was performed using only admission day and in-hospital events occurring before RF. RESULTS: A total of 511 patients from 14 sites (median age 57 years, admission model for end-stage liver disease [MELD]-Na 23) were enrolled: RF developed in 15%; AKI occurred in 24%; and 11% developed nosocomial infections (NI). At admission, patients who developed RF had higher MELD-Na, gastrointestinal (GI) bleeding/AKI-related admission, and prior infections/ascites. During hospitalization, RF developers had higher NI (especially respiratory), albumin use, and other organ failures. RF was higher in patients receiving albumin (83% vs 59%, P < 0.0001) with increasing doses (269.5 ± 210.5 vs 208.6 ± 186.1 g, P = 0.01) regardless of indication. Admission for AKI, GI bleeding, and high MELD-Na predicted RF. Using all variables, NI (odds ratio [OR] = 4.02, P = 0.0004), GI bleeding (OR = 3.1, P = 0.002), albumin use (OR = 2.93, P = 0.01), AKI (OR = 3.26, P = 0.008), and circulatory failure (OR = 3.73, P = 0.002) were associated with RF risk. DISCUSSION: In a multicenter inpatient cirrhosis study of patients not exposed to terlipressin, 15% of patients developed RF. RF risk was highest in those admitted with AKI, those who had GI bleeding on admission, and those who developed NI and other organ failures or received albumin during their hospital course. Careful volume monitoring and preventing nosocomial respiratory infections and renal or circulatory failures could reduce this risk.
Abstract 13828: Aptamer Proteomics for Biomarker Discovery in Heart Failure With Preserved Ejection Fraction: The PARADIGM-HF Proteomic Sub-Study
Claggett, Brian , Xu, Dongchu , Serrano‐Fernández, Pablo , Wandel, Simon , Zhao, Faye, Chutkow, William A., O’Donnell, Christopher J. , Prescott, Margaret F., Lefkowitz, Martin, Gimpelewicz, Claudio , Gou, Liangke , Redfield, Margaret M. , Rouleau, Jean L. , ZANNAD, Faiez, Solomon, Scott D. , Patel‐Murray, Natasha , Zhang, Luqing , Xu, Huilei , Healey, Margaret L. , Turner, Gordon M , Chen, Chien‐Wei , Yates, Denise P , Beste, Michael T , Desai, Akshay S , Jhund, Pardeep S. , Packer, Milton , Pfeffer, Marc Alan , Zannad, Faı̈ez , Zile, Michael R. , McMurray, John J.V. , Mendelson, Michael M , Solomon, Scott David , Cunningham, Jonathan W.

Mayo Clinic

Circulation | November 6, 2023 | Volume: 148 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.148.suppl_1.13828 Get It

Introduction: Prognostic markers and biological pathways linked to detrimental clinical outcomes in heart failure with preserved ejection fraction (HFpEF) remain incompletely defined. Goal: To identify serum proteins associated with risk for HF hospitalization (HFH) and cardiovascular (CV) death in patients with HFpEF, including proteins with differential associations with clinical outcomes in HFpEF compared to HFrEF. Methods: We measured serum levels of 4123 unique proteins in 1117 patients with HFpEF in the PARAGON-HF trial using a modified aptamer proteomic assay. Baseline protein concentrations significantly associated with total HFH and CV death were identified by recurrent events regression, accounting for multiple testing, adjusted for age, sex, treatment, and anticoagulant use, and compared to 2515 patients with HFrEF from the PARADIGM-HF and ATMOSPHERE trials. Results: We identified 288 proteins to be robustly associated with the risk of HFH and CV death (335 events over an average of 2.7 years of follow-up) in a HFpEF trial population. Proteins most strongly related to HFpEF outcomes included B2M, TIMP1, SERPINA4, and SVEP1 ( Figure ). Protein-outcome associations in patients with HFpEF did not markedly differ compared to HFrEF. Just 3 proteins (APOE, RTF1, and VWF) were differentially associated with outcomes between the HF subtypes (FDR <0.05). A proteomic risk score derived in HFpEF patients was not superior to a previous proteomic score derived in HFrEF nor to clinical risk factors, NT-proBNP, or high-sensitivity cardiac troponin. Conclusions: Numerous serum proteins linked to metabolic, coagulation, and extracellular matrix regulatory pathways were associated with worse HFpEF prognosis. SVEP1, a cell adhesion protein recently identified as a HFrEF prognosis biomarker, also strongly predicted risk in HFpEF. Our results demonstrate substantial similarities in serum proteomic risk markers across the EF spectrum.
Efficacy and Safety of Teprotumumab in Patients With Thyroid Eye Disease of Long Duration and Low Disease Activity
Couch, Steven M., Wester, Sara T. , Fowler, Brian , Liu, Catherine Y., Subramanian, Prem S. , Tang, Rosa A. , Nguyen, Quang T., Maamari, Robi N. , Karon, M , Douglas, Raymond S , Karon, Michael , Nguyen, Quang T, Ugradar, Shoaib , Hsu, Kate, Stan, Marius N.

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | November 5, 2023 | Volume: 109 | Issue: 1 | Pages: 25-35

10.1210/clinem/dgad637 | PMID 37925673 Get It

AbstractContextEarly inflammatory thyroid eye disease (TED) can lead to symptomatic chronic disease, including disabling proptosis. Teprotumumab, an insulin-like growth factor-1 receptor (IGF-1R) inhibitor, previously demonstrated efficacy in acute, high-inflammation TED trials.ObjectiveWe present data from the first placebo-controlled trial with teprotumumab in chronic/low disease activity TED.MethodsThis randomized double-masked, placebo-controlled trial, conducted at 11 US centers, enrolled adult participants with TED duration of 2 to 10 years, Clinical Activity Score (CAS) ≤ 1 or no additional inflammation or progression in proptosis/diplopia for ≥1 year, proptosis ≥3 mm from before TED and/or from normal, euthyroid/mildly hypo/hyperthyroid, no prior teprotumumab, and no steroids within 3 weeks of baseline. Patients received (2:1) intravenous teprotumumab or placebo once every 3 weeks (total 8 infusions). The primary endpoint was proptosis (mm) improvement at Week 24. Adverse events (AEs) were assessed.ResultsA total of 62 (42 teprotumumab and 20 placebo) patients were randomized. At Week 24, least squares mean (SE) proptosis improvement was greater with teprotumumab (−2.41 [0.228]) than with placebo (−0.92 [0.323]), difference −1.48 (95% CI −2.28, −0.69; P = .0004). Proportions of patients with AEs were similar between groups. Hyperglycemia was reported in 6 (15%) vs 2 (10%) and hearing impairment in 9 (22%) vs 2 (10%) with teprotumumab and placebo, respectively. AEs led to discontinuation in 1 teprotumumab (left ear conductive hearing loss with congenital anomaly) and 1 placebo patient (infusion-related). There were no deaths.ConclusionTeprotumumab significantly improved proptosis vs placebo in longstanding/low inflammation TED, demonstrating efficacy regardless of disease duration/activity. The safety profile was comparable to that previously reported.
Right ventricular outflow tract obstruction associated with neointimal tissue accumulation and distortion of the Harmony TPV25 stent frame: Potential mechanisms and treatment
Balzer, David T. , Asnes, Jeremy D. , Morray, Brian H. , Gillespie, Matthew J. , McElhinney, Doff B. , Cabalka, Allison K. , Asnes, Jeremy D , Morray, Brian H , McElhinney, Doff B , Steinberg, Zachary Louis

Mayo Clinic

Catheterization and Cardiovascular Interventions | November 5, 2023 | Volume: 102 | Issue: 6 | Pages: 1078-1087

10.1002/ccd.30901 | PMID 37925624 Get It

AbstractBackgroundThe Harmony TPV25 transcatheter pulmonary valve (Medtronic Inc.) is constructed with a self‐expanding stent frame comprising six zigged nitinol wires sewn together and covered with knitted polyester fabric, with flared inflow and outflow ends and a porcine pericardial valve sutured to the central portion of the device. It was approved for treatment of pulmonary regurgitation after prior right ventricular outflow tract repair in 2021. Early outcomes of this procedure have been excellent, but little is known about valve durability or ultimate mechanisms of dysfunction.MethodsWe collected data on patients who underwent reintervention for TPV25 dysfunction and described findings related to distortion of the stent frame and tissue accumulation.ResultsWe describe six patients who underwent valve‐in‐valve implant for TPV25 obstruction (peak catheterization gradient peak 28–73 mmHg) 10–28 months after implant. In all cases, there was tissue accumulation within the inflow and valve‐housing segments of the device and deformation of the self‐expanding valve frame characterized by variable circumferential narrowing at the junction between the valve housing and the inflow and outflow portions of the device, with additional geometric changes in all segments. All six patients underwent valve‐in‐valve implant that results in a final peak gradient ≤10 mmHg and no regurgitation.DiscussionThe occurrence of short‐term Harmony TPV25 dysfunction in multiple patients with a similar appearance of frame distortion and tissue accumulation within the inflow and valve housing portions of the device suggests that this may be an important failure mechanism for this valve. Potential causes of the observed findings are discussed. It is possible to treat this mechanism of TPV25 dysfunction with valve‐in‐valve implant using balloon expandable transcatheter valves.
Th17-inducing dendritic cell vaccines stimulate effective CD4 T cell-dependent antitumor immunity in ovarian cancer that overcomes resistance to immune checkpoint blockade
Luo, Yan , Shreeder, Barath , Jenkins, James W. , Lamichhane, Purushottam , Zhou, Kexun , Bahr, Deborah, Kurian, Sophia, Jones, Katherine A. , Daum, Joshua , Dutta, Navnita , Necela, Brian M. , Cannon, Martin J. , Block, Matthew S. , Knutson, Keith L. , Shi, Huashan, Bahr, Deborah A, Daum, Joshua I, Knutson, Keith L. , Jenkins, James William , H, Shi , Jones, Katherine A

Mayo Clinic

Journal for ImmunoTherapy of Cancer | November 2, 2023 | Volume: 11 | Issue: 11 | Pages: e007661

10.1136/jitc-2023-007661 | PMID 37918918 Get It

Background Ovarian cancer (OC), a highly lethal cancer in women, has a 48% 5-year overall survival rate. Prior studies link the presence of IL-17 and Th17 T cells in the tumor microenvironment to improved survival in OC patients. To determine if Th17-inducing vaccines are therapeutically effective in OC, we created a murine model of Th17-inducing dendritic cell (DC) (Th17-DC) vaccination generated by stimulating IL-15 while blocking p38 MAPK in bone marrow-derived DCs, followed by antigen pulsing. Methods ID8 tumor cells were injected intraperitoneally into mice. Mice were treated with Th17-DC or conventional DC (cDC) vaccine alone or with immune checkpoint blockade (ICB). Systemic immunity, tumor associated immunity, tumor size and survival were examined using a variety of experimental strategies. Results Th17-DC vaccines increased Th17 T cells in the tumor microenvironment, reshaped the myeloid microenvironment, and improved mouse survival compared with cDC vaccines. ICB had limited efficacy in OC, but Th17-inducing DC vaccination sensitized it to anti-PD-1 ICB, resulting in durable progression-free survival by overcoming IL-10-mediated resistance. Th17-DC vaccine efficacy, alone or with ICB, was mediated by CD4 T cells, but not CD8 T cells. Conclusions These findings emphasize using biologically relevant immune modifiers, like Th17-DC vaccines, in OC treatment to reshape the tumor microenvironment and enhance clinical responses to ICB therapy.
Association of Frailty and Complications Following Prostate Biopsy: Results From a Population-Based, Privately Insured Cohort
Kiani, Kayvon, Kim, Simon P. , Pessoa, Rodrigo Rodrigues , Gershman, Boris , Gonzalez, Christopher , Molina, Elizabeth, DaSilva, Rodrigo Donalisio, Chapin, Brian F. , Ballon‐Landa, Eric , Molina, Elizabeth, Warren, Adam , DaSilva, Rodrigo Donalisio

Mayo Clinic

Urology Practice | November 2, 2023 | Volume: 11 | Issue: 1 | Pages: 117-122

10.1097/upj.0000000000000476 | PMID 37914379 Get It

207 The spatially-resolved proteomic atlas of the tumor immune architecture of HER2-positive breast cancer and response to neoadjuvant anti-HER2 therapy-based chemotherapy
Chumsri, Saranya , Kachergus, Jennifer M., Shi, Ji , Liu, Yi , Ma, Yaohua , Bonnett, Shilah A. , Conner, Mark , Piazza, Erin , Filanoski, Brian, Meredith, Rhonda, Kang, Christine , Isgur, Lesley, Geiss, Gary , Beechem, Joseph , Thompson, E. Aubrey , Rosenbloom, Alyssa B. , Kang, Christine, Hoang, Margaret L.

Mayo Clinic

Regular and Young Investigator Award Abstracts | October 31, 2023 | Volume: No volume available | Issue: No issue available | Pages: A235-A235

10.1136/jitc-2023-sitc2023.0207 Get It

Treatment modalities and survival outcomes in prostate cancer parenchymal brain metastasis
Mahmoud, Ahmed , Childs, Daniel S. , Ahmed, Mohamed E. , Johnson, Geoffrey B. , Orme, Jacob J. , Stish, Bradley J. , Phillips, Ryan , Andrews, Jack R. , Kwon, Eugene D., Mahmoud, Ahmed M , Phillips, Ryan M., Davis, Brian J. , Andrews, Jack R , Childs, Daniel S , Johnson, Geoffrey B , Ahmed, Mohamed , Kendi, A. Tuba , Park, Sean S.

Mayo Clinic

The Prostate | October 30, 2023 | Volume: 84 | Issue: 3 | Pages: 237-244

10.1002/pros.24643 | PMID 37899635 Get It

AbstractBackgroundProstate cancer (PCa) parenchymal brain metastases are uncommon and troubling observations in the course of the disease. Our study aims to evaluate the prevalence of brain metastases among PCa patients while reporting various therapeutic modalities, clinical features, and oncological outcomes.MethodsWe retrospectively identified 34 patients with parenchymal brain metastasis out of 4575 patients using a prospectively maintained database that contains clinicopathologic characteristics of PCa patients between January 2012 and December 2021. Based on the three treatment modalities used, the patients were divided into three groups: stereotactic radiosurgery (SRS), whole brain radiotherapy (WBRT), and systemic therapy alone. The Kaplan–Meier curve was used to calculate overall survival [OS] probability and the Cox proportional hazards regression model was used to compare between groups.ResultsAt the time of brain metastasis diagnosis, the median age was 66 years, the median (interquartile range [IQR]) prostate‐specific antigen (PSA) was 2.2 (0.1–26.6) ng/ml and the median (IQR) months from initial PCa diagnosis to brain metastasis development was 70.8 (27.6–100.9). The median (IQR) primary Gleason score was 8 (7–9) and over a median (IQR) follow‐up time of 2.2 (1.2–16.5) months, 76.5% (n = 26) of the patients died. Thirteen (38.2%) patients had solitary lesion, whereas 21 (61.8%) had ≥2 lesions. The lesions were supratentorial in 19 (55.9%) patients, infratentorial in six (17.6%), and both sides in nine (26.5%). Among all 34 patients, 10 (29.4%) were treated with SRS, seven (20.6%) with WBRT, and 17 (50%) with systemic therapy alone. OS varied greatly between the three treatment modalities (log‐rank test, p = 0.049). Those who were treated with SRS and WBRT had better OS compared with patients who were treated with systemic therapy alone (hazard ratio: 0.37, 95% confidence interval: 0.16–0.86, p = 0.022).ConclusionsIn our single‐institutional study, we confirmed that PCa brain metastasis is associated with poor survival outcomes and more advanced metastatic disease. Furthermore, we found that SRS and WBRT for brain metastasis in patients with recurrent PCa appear to be associated with improved OS as compared with systemic therapy alone and are likely secondary to selection bias.